Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Nicole R. Hadas Sells 63,186 Shares

Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) SVP Nicole R. Hadas sold 63,186 shares of Akebia Therapeutics stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $1.22, for a total value of $77,086.92. Following the completion of the sale, the senior vice president now owns 524,344 shares of the company’s stock, valued at $639,699.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Akebia Therapeutics Trading Up 0.0 %

NASDAQ AKBA opened at $1.21 on Friday. Akebia Therapeutics, Inc. has a 52 week low of $0.24 and a 52 week high of $1.63. The business has a 50 day moving average price of $0.81 and a 200-day moving average price of $0.67. The company has a debt-to-equity ratio of 3.65, a quick ratio of 1.21 and a current ratio of 1.46.

Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last released its quarterly earnings data on Thursday, March 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $55.18 million during the quarter, compared to the consensus estimate of $48.35 million. Akebia Therapeutics had a negative return on equity of 235.17% and a negative net margin of 20.79%. On average, analysts predict that Akebia Therapeutics, Inc. will post -0.33 earnings per share for the current year.

Institutional Investors Weigh In On Akebia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Icon Wealth Partners LLC bought a new stake in Akebia Therapeutics during the first quarter worth $28,000. BNP Paribas Arbitrage SA grew its holdings in Akebia Therapeutics by 123.7% during the second quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 50,066 shares in the last quarter. Mirabella Financial Services LLP bought a new stake in Akebia Therapeutics during the first quarter worth $40,000. HighTower Advisors LLC grew its holdings in Akebia Therapeutics by 18.4% during the first quarter. HighTower Advisors LLC now owns 70,350 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 10,925 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Akebia Therapeutics by 1,916.5% during the first quarter. JPMorgan Chase & Co. now owns 81,547 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 77,503 shares in the last quarter. Institutional investors own 28.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. HC Wainwright lifted their target price on Akebia Therapeutics from $1.25 to $2.00 in a report on Wednesday, April 26th. StockNews.com downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 15th.

About Akebia Therapeutics

(Get Rating)

Akebia Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.